Executive Summary
The case for early TAVR in asymptomatic severe aortic stenosis just got broader: a new Circulation: Cardiovascular Interventions subanalysis of EARLY TAVR shows the benefit holds across every age band from 65 to 80+, with the largest absolute stroke reduction in the youngest (13%, age 65-69) and oldest (12.3%, ≥80) groups — and roughly a third of younger surveillance patients crossed over with an acute valve syndrome. A JACC transportability analysis of COAPT in 15,275 TVT Registry patients estimates a 17.0% absolute reduction in HF hospitalization and 15.4% reduction in 2-year mortality if real-world M-TEER patients had received COAPT-protocol care, validating the ESC 2025 Class I upgrade. STS data presented by Hawkins show TAVR explant is now the fastest-growing US cardiac surgery (~800 cases in 2023), with isolated SAVR-after-TAVR mortality down to 3.5% in the contemporary era — which tightens the lifetime-management case against first-line TAVR in 65-year-olds.
- EARLY TAVR subanalysis: relative benefit of early TAVR over surveillance is age-independent across 65-80+, with median time-to-conversion 11 months (Circulation Cardiovasc Interv).
- CLASP IID 1-year data: optimal M-TEER result (residual MR ≤1+ AND MVG ≤5 mmHg) yielded 89.5% vs 79.7% freedom from MAE; when forced to choose, prioritize MR reduction over gradient (JACC Cardiovasc Imaging).
- Updated meta-analysis of 9 RCTs (n=11,696): cerebral embolic protection during TAVR did not reduce all-cause stroke (RR 0.92, p=0.43), disabling stroke, or mortality (Frontiers Cardiovasc Med).
- Mini-Mitral International Registry (n=2,563): full endoscopic MV surgery delivered 82.2% repair rate, 2.5% in-hospital mortality, 94.9% repair rate in the degenerative subgroup (J Vis Surg).
- Edwards received FDA approval for a surgical tricuspid valve, broadening its right-sided portfolio as TTVR scales.
What to watch: New York Valves 2026 next week will surface late-breaking TR and bicuspid TAVR data, with expected updates on TRISCEND II durability and EARLY TAVR longer-term follow-up.
Aortic Valve (TAVR/TAVI)
The EARLY TAVR age subanalysis collapses one of the last remaining defenses of watchful waiting: the relative benefit of early intervention is independent of age across 65-80+ years (Circulation Cardiovasc Interv, n=901). The 13% absolute stroke reduction in the 65-69 cohort and a third of those patients crossing over with acute valve syndrome are the numbers that should move clinicians. [NOTABLE] ESC 2025 Class IIa endorses early intervention in asymptomatic severe AS; ACC/AHA 2020 still recommends SAVR for patients <65 on durability grounds — exactly the age band where the EARLY TAVR stroke signal is strongest. The surgical counterweight: STS explant data (Hawkins) document 5,700+ SAVR-after-TAVR cases, ~800 explants in 2023 alone, and a contemporary isolated explant mortality of 3.5%. The upfront opportunity costs of TAVR-first — lost coronary access, neo-skirt commissural complications, finite TAV-in-TAV runway — are quantifiable now, not theoretical. A meta-analysis of 9 RCTs (n=11,696) confirms cerebral embolic protection does not reduce stroke (RR 0.92, p=0.43) (Frontiers Cardiovasc Med). A Mayo series of 61 post-TAVR cardiac operations reports 6.6% operative mortality with infective endocarditis (36%) and nonstructural deterioration (36%) as the leading SAVR indications (ICVTS) — a procedural-risk floor the lifetime-management calculus must clear.
Mitral Valve (MitraClip, PASCAL, TMVR)
Secondary MR therapy is a Class I question under ESC 2025; the technical execution still defines outcome. The JACC COAPT transportability analysis applied inverse odds of participation weighting to 7,289 trial-eligible TVT Registry patients and estimated a 17.0% absolute reduction in HF hospitalization and 15.4% reduction in mortality at 2 years — effect sizes statistically indistinguishable from COAPT itself. This is the cleanest validation yet of the ESC 2025 Class I (LOE A) upgrade for M-TEER in ventricular SMR and sharpens the tension with ACC/AHA 2020's still-Class IIa positioning. The limitation is structural: real-world TVT patients had less ischemic etiology (34.1% vs 60.8%) and more 4+ MR (79.4% vs 47.9%) — these are not COAPT patients, and the analysis is a weighted estimate, not a comparative outcome. The CLASP IID 1-year analysis in 284 PASCAL patients delivers the actionable finding: when forced to trade off, residual MR ≤1+ with gradient >5 mmHg beats MR ≥2+ with low gradient on MAE (87.7% vs 75.5%) and mortality. Prioritize the leak. The surgical benchmark against which any M-TEER for primary MR must be measured comes from the Mini-Mitral International Registry (n=2,563): 94.9% repair rate in degenerative disease at 1.4% mortality — the durable-repair standard ESC 2025 invokes in upgrading asymptomatic primary MR repair to Class I. Both ACC/AHA 2020 and ESC 2025 rate TEER for primary MR as Class IIa only when surgical risk is prohibitive.
Tricuspid Valve (TriClip, TTVR)
Edwards' FDA approval for a dedicated surgical tricuspid valve arrives as ESC 2025 has moved transcatheter TR therapy to Class IIa (LOE A) and elevated symptomatic primary TR surgery to Class I — both upgrades built on TRILUMINATE Pivotal, Tri.Fr, and TRISCEND II. ACC/AHA 2020 did not address transcatheter TR therapy; the ESC 2025 Class IIa recommendation is the operative standard in Europe and is pulling US practice ahead of the next guideline update. The gating issue for both surgical and transcatheter options remains RV function at referral: a rat TR model via transjugular coronary stent implantation showed FAC dropped 33.9% and TAPSE 36.8% at 8 weeks, confirming that the RV decompensation window is short once severe TR is established. ESC 2025 explicitly calls out the historical too-late-referral pattern; the patients who do best — with surgery or transcatheter repair — are those referred before RV failure crystallizes. A new ACC trial (NCT07623083) will evaluate an integrated management algorithm for TAVI patients with concomitant MR or TR, addressing the multi-valve question both current guidelines defer to Heart Team discretion.
Surgical vs. Transcatheter Comparisons
The STS TAVR-explant data (Hawkins, Cardiovascular Business) reframe the SAVR-vs-TAVR decision in patients under 70 as a lifetime-management question: contemporary isolated SAVR-after-TAVR mortality is 3.5%, but the upfront cost of TAVR-first — losing coronary access, neo-skirt commissural complications, finite TAV-in-TAV runway — is non-trivial and now quantified. ESC 2025's framework (SAVR preferred <70, TAVI ≥70 with suitable tricuspid anatomy and transfemoral access) handles this calculus more explicitly than ACC/AHA 2020's <65 SAVR threshold. On the mitral side, the endoscopic MV registry's 94.9% repair rate at 1.4% mortality in degenerative disease is the surgical benchmark any M-TEER for primary MR must clear — and neither ACC/AHA 2020 nor ESC 2025 has moved TEER for primary MR above Class IIa for anything short of prohibitive surgical risk.
Device & Technology
A prospective 10-patient series combined pulsed-field ablation with M-TEER through a single transseptal access: 90% sinus rhythm at 6 months, no strokes or tamponade, median procedure time 102 minutes. Single-center, no comparator, n=10 — the tissue selectivity of PFA makes one-stop AF+MR therapy plausible, not proven. A separate staged-annuloplasty-then-TEER case using Carillon to reduce a 7.4-cm annulus before MitraClip extends transcatheter MR therapy into anatomies that previously demanded surgery — feasibility only, not standard of care. The CALLY index (CRP-albumin-lymphocyte composite) was an independent predictor of post-TAVI mortality in 330 patients (HR 0.965, AUC 0.730) — a simple risk-stratification adjunct from a retrospective, single-center series.
Regulatory & Policy
Edwards' FDA approval of a dedicated surgical tricuspid valve gives surgeons a purpose-built option as ESC 2025's Class I upgrade for symptomatic primary TR surgery drives referral volume. Hawkins' parallel argument in the STS analysis — that the field should resist proposals to reduce TVT registry requirements — is the policy fight worth tracking. Without long-term TAVR durability data beyond 10 years, the lifetime-management debate has no empirical resolution.
Industry & Market
Edwards announced Theodora Mistras as CFO on the same day it secured the surgical tricuspid approval — a leadership transition timed around its structural heart growth thesis. TD Cowen raised its EW price target to $104 from $97, maintaining a Buy.
Financial Analysis
The structural heart trade is bifurcating. Edwards held flat over six months on the strength of its TAVR + tricuspid franchise — analysts see this as structural heart growth, not just a TAVR story — while Boston Scientific's structural exposure has been the casualty of a -51% six-month drawdown despite continued Watchman and PFA momentum. The EARLY TAVR age subanalysis and ESC 2025's Class I TEER upgrade favor Edwards (SAPIEN, PASCAL) and Abbott (MitraClip, TriClip). Anteris (+78% over 6 months) continues to price in DurAVR optimism on thin clinical data — the -7.77% pullback is the volatility that defines pre-commercial valve names. Medtronic's +5.7% single-day move came on broader medtech rotation, not valve-specific news; structural heart remains a smaller piece of the MDT story.
Valve Industry Stocks
Edwards Lifesciences (EW)
- Price: $86.00 (-1.89% day) | 6-month: +0.26% | 52-wk range: $72.30-$89.14
- Market cap: $49.5B | P/E (trailing) 46.5 | P/E (fwd) 25.5 | Beta 0.87
- Analyst target: $96.92 (Buy, 26 analysts; range $84-$110); TD Cowen raised to $104
- Next earnings: 2026-07-23 (EPS est $0.74; Rev est $1.70B)
- Catalysts: FDA approval for surgical tricuspid valve; new CFO Theodora Mistras; ESC 2025 TR upgrades expanding Edwards' right-sided TAM
Medtronic (MDT)
- Price: $77.95 (+5.69% day) | 6-month: -22.38% | 52-wk: $73.31-$106.33
- Market cap: $100.1B | P/E (trailing) 20.9 | P/E (fwd) 12.1
- Analyst target: $103.15 (Buy, 26 analysts)
- Next earnings: 2026-08-18 (EPS est $1.39; Rev est $9.49B)
- Catalysts: Evolut Low Risk long-term follow-up remains the structural heart anchor; broader portfolio drove today's rally
Abbott (ABT)
- Price: $86.99 (flat) | 6-month: -29.84% | 52-wk: $81.97-$139.06
- Market cap: $151.5B | P/E (trailing) 24.4 | P/E (fwd) 14.4 | Beta 0.65
- Analyst target: $117.29 (Buy, 24 analysts)
- Next earnings: 2026-07-16 (EPS est $1.28; Rev est $12.53B)
- Catalysts: Direct beneficiary of ESC 2025 Class I M-TEER upgrade (MitraClip) and Class IIa transcatheter TR upgrade (TriClip); COAPT transportability data validates real-world utility
Boston Scientific (BSX)
- Price: $47.69 (flat) | 6-month: -51.20% | 52-wk: $47.16-$109.50
- Market cap: $70.9B | P/E (trailing) 19.95 | P/E (fwd) 12.8 | Beta 0.62
- Analyst target: $78.87 (Strong Buy, 30 analysts; range $55-$106)
- Next earnings: 2026-07-29 (EPS est $0.83; Rev est $5.38B)
- Catalysts: Acurate neo2 trial readouts and structural heart positioning remain under pressure; the -51% drawdown is the sector's biggest story
Anteris Technologies (AVR.AX)
- Price: A$11.99 (-7.77% day) | 6-month: +77.63% | 52-wk: A$4.68-$13.80
- Market cap: A$1.2B | P/E (fwd) -5.5 | Beta 0.59
- Catalysts: DurAVR THV clinical pipeline; volatility reflects pre-commercial valve dynamics
The six-month spread between EW (+0.3%) and BSX (-51.2%) tells the structural heart story: incumbents with broad TAVR/M-TEER/TR portfolios are weathering rotation; companies whose structural heart segments are smaller pieces of bigger stories (MDT, ABT) have followed broader medtech weakness; pure-play challengers (AVR.AX) trade on milestones, not earnings. ESC 2025's M-TEER and transcatheter TR upgrades are tailwinds that haven't yet fully reflected in pricing.
Clinical Trial Updates
Aortic
- NCT07623083 — Evaluation of a Management Algorithm for TAVI Patients With Concomitant Mitral or Tricuspid Regurgitation | Status: Not Yet Recruiting | Enrollment: 300 | Sponsor: Josep Rodes-Cabau. Addresses the multi-valve gap left by ACC/AHA 2020 and ESC 2025 — both guidelines defer concurrent MR/TR management at TAVI to Heart Team discretion.
Landmark trials referenced in today's evidence:
- [LANDMARK] EARLY TAVR (NCT03042104) — age subanalysis published today; benefit consistent across 65 to ≥80 years.
- [LANDMARK] COAPT — transportability analysis confirms generalizability to US M-TEER practice for SMR.
- [LANDMARK] CLASP IID (NCT03706833) — 1-year hemodynamic outcomes show MR reduction trumps gradient preservation.
Social & Conference Highlights
New York Valves 2026 previews emphasize late-breaking structural heart research; expect data on bicuspid TAVR — where both ACC/AHA 2020 and ESC 2025 hold at Class IIb — and longer-term TRILUMINATE/TRISCEND II outcomes.
Forward look: The EARLY TAVR age data plus the STS explant trajectory are pulling the field in opposite directions on the same patient — the 67-year-old with asymptomatic severe AS. The next ACC/AHA update will have to reconcile the case for intervening earlier with the case for keeping TAVR off the table until later in life. Watch New York Valves 2026 for the durability data that decides which argument wins.